Novo Nordisk Sues Hims & Hers Over $49 Semaglutide Pill Patent
Novo Nordisk has sued Hims & Hers for infringing U.S. Patent 8,129,343 with its $49/month compounded semaglutide pill. The action, following an FDA advisory that non-approved GLP-1 products could face restrictions, triggered a 3.7% gain in Novo Nordisk shares.
1. Lawsuit Against Hims & Hers
Novo Nordisk filed suit alleging infringement of U.S. Patent 8,129,343 by Hims & Hers Health’s compounded semaglutide pill, specifically targeting the unapproved $49 introductory offer. The action underscores the company’s commitment to protecting its Wegovy franchise from generic-like competitors.
2. FDA Advisory and Hims Response
Following an FDA warning on compounded GLP-1 drugs, Hims & Hers ceased its semaglutide pill offering, acknowledging regulatory risks. The FDA statement did not distinguish between oral and injectable formulations, raising broader compliance concerns.
3. Impact on Novo Nordisk Shares
Shares of Novo Nordisk climbed 3.7% after the legal filing, reflecting investor confidence in reduced competition for its GLP-1 portfolio. Industry analysts view the lawsuit as a strategic move to maintain pricing power in the weight-loss drug market.